Our Group and Brands
We believe in brand power. From our pharmaceuticals to our consumer health products, our label stands for trust and quality.
Scroll Down
Our Company
Breathe Life Sciences
Breathe Life Sciences (“BLS”) is the Australian market leader in the manufacture of medicinal cannabis, MDMA, and Psilocybin. The Group manufactures and supplies pharmaceutical and consumer health products in Australia, the UK and Europe. Its clients include pharmaceutical distributors, clinics, pharmacies, manufacturers, and prescription medicine brand owners.
BLS operates in areas of unmet clinical need, manufacturing and supplying medicines designed to support patients for whom traditional therapies and existing treatment options have not delivered adequate outcomes.
Breathe Life Sciences is licensed by the Therapeutic Goods Administration (“TGA”) to manufacture medicinal cannabis, MDMA, and Psilocybin products, certified compliant with EU GMP (European Good Manufacturing Practices) standards. Breathe Life Sciences holds licenses to import, export, wholesale, and manufacture Schedule 3, 4, 8, and 9 controlled substances. Outside of Australia, the business has manufacturing and distribution centres in Japan, the United Kingdom, and Czechia (Europe), operating wholesale supply of API, starting materials, white label services and direct to consumer supply of its trademarked Dr Watson® brand.
Our Brands
Our Brands
From our pharmaceuticals to our consumer health products, our label stands for quality and trust. Our vision as a group has been to focus on data-driven product and process development, building world class pharmaceutical service levels from procurement to manufacture and distribution. We operate as an industry partner, helping our clients build and grow compliantly.
As a life sciences company, our work, products and services are dedicated to improving quality of life as well as ease of access to therapeutic goods for unmet needs. We operate in nascent markets and aspire to change the way the world prevents and treats disease with unregistered alternative medicines, consumer health products, and technology.
